For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Vyndamax and Tafamidis meglumine represents a genuine breakthrough . These novel therapies protect the transthyretin protein, halting its harmful build-up and reducing the burden of the condition . People are now experiencing benefits in